Roche Holding Ltd · SIX:RO
Roche — Jefferies Global Healthcare Conference 2025
21 slides from Roche's conference presentation, Jun 4, 2025
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: In the middle of the portfolio transition
In the middle of the portfolio transition Alan Hippe | CFO Roche Jefferies HC conference NY, 4 June 2025
Slide 4: Business update
Business update Strategy update Pipeline update Outlook
Slide 5: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio Diagnostics: Molecular Lab and Q1 2025 sales Pathology Lab driving growth; China 0% (CHFbn, YoY CER growth) impacted by healthcare pricing reforms Phesgo: Conversion rate climbing to 47% 3.5 Alecensa: Geographic expansion in adj. ALK+ NSCLC 6.0 +6% 0.9 CHF 1
Slide 6: A solid base to deliver future growth
A solid base to deliver future growth Pipeline and business development to add significant upside potential illustrative Business development • BD to accelerate pipeline portfolio • In-house pipeline with upside Pharma pipeline potential • On-market Pharma portfolio to deliver growth until 2028 Sale
Slide 7: Consensus outlook 2024-29
Consensus outlook 2024-29* Growth driven by our young on-market portfolio; potential pipeline up-side Biosimilar gap (24-29) Consensus sales growth (24-29) Potential up-side 2026+ Vabysmo 3.6 bn Itovebi 1.2 bn Assets with low to no coverage in Ronapreve 015bn Lucentis 0.1 bn Ocrevus 1.0 bn current s
Slide 8: Roche with full Pharma and Diagnostics value chains in the US
Roche with full Pharma and Diagnostics value chains in the US Commitment to invest USD 50bn into R&D and PP&E in the US until the end of the decade 13+1* manufacturing and 15+1* R&D sites in the US Biologics productivity evolution 2000 to 2030 ▪ US investments of USD 67bn over the last 10 years, inc
Slide 9: Strategy update
Business update Strategy update Pipeline update Outlook
Slide 10: Strategic review completed and in implementation
0 Strategic review completed and in implementation Ten-Year Ambitions Digital Health Group Group People & Strategy AI U.S. China Sustainability Strategy Culture Data Diagnostics Pharma Divisional Strategies Formation of Near Patient Care R&D Excellence Infectious Cardiovascular- Oncology2 Neurology
Slide 11: R&D Excellence: Our solutions
R&D Excellence: Our solutions We identified six solutions to achieve top quartile performance - with implementation ongoing Adopt a unified portfolio Transform our portfolio Access the best external framework management & governance innovation Introduce the ‘Bar’ to recognize assets Reconfigure end-
Slide 12: Pipeline prioritization since Q2 2023
Pipeline prioritization since Q2 2023 Pipeline changes since Q2’23 siRNA targeting AGT in Allogeneic CAR-T in hypertension Onco/Heme, Immuno and Neuro * 8 -8 81 4 -3 1 27 Additions Long-acting amylin analog -5 3 • 16 Ph I additions from -4 3 in obesity diabetes -9 pRED/gRED/Chugai 5 -5 -2 72 3 • 11
Slide 13: Roche's commitment to become a leader in CVRM
Roche’s commitment to become a leader in CVRM Complementing our obesity portfolio and laying the foundation for future innovation in CVRM Pharmaceuticals Diagnostics * ** CT-173 (PYY) CT-388 (GLP-1/GIP RA) CT-868 (GLP-1/GIP RA) CT-996 (GLP-1 RA) Petrelintide (Long-acting amylin analogue) GYM 329 (an
Slide 14: Diagnostics key launches
Diagnostics key launches Key new or upcoming launches are creating significant leaps forward in Diagnostics cobas Accu-Chek Roche Sequencing LumiraDx Mass Spectrometry SmartGuide CGM Solution First fully automated Multimodal technology Real-time glucose monitoring Combines two innovations for high M
Slide 15: Pipeline update
Business update Strategy update Pipeline update Outlook
Slide 16: Q1 Pharma pipeline update
Q1 Pharma pipeline update Q1 key updates: Ph III Go for trontinemab in AD and for NXT007 in hemophilia A; Zealand Pharma collaboration New Molecular Entities (NME) giredestrant fenebrutinib vamikibart HR+ BC RMS, PPMS DME, UME Itovebi (inavolisib) Elevidys1 CT-388 Pi3Km BC DMD Obesity +/- T2D divara
Slide 17: 2025 Pharma pipeline
2025 Pharma pipeline 7 NMEs with Ph III enabling readouts expected New Molecular Entities (NME) giredestrant fenebrutinib vamikibart HR+ BC RMS, PPMS DME/UME Itovebi (inavolisib) Elevidys CT-388 Pi3Km BC DMD Obesity +/- T2D divarasib GYM 329 CT-868 KRAS+ NSCLC, CRC SMA, FSHD T1D with BMI ≥25 tiragol
Slide 18: Outlook
Business update Strategy update Pipeline update Outlook
Slide 19: 2025 guidance
2025 guidance LOE impact of CHF 1.2bn expected for 2025 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant Exchange Rates (avg full year 2024); LOE: Loss of exclusivity in
Slide 20: Expected 2025 currency impact
Expected 2025 currency impact FY 2025 impact of -4%p on Group sales expected assuming 07 May 2025 rates remain stable until the end of 2025 USD / CHF Assumed avg. YTD 2025 +3% 0% +1% +1% Assuming the 31 March 2025 exchange rates remain stable until end of 2025, 0.90 0.89 0.89 0.89 2025 impact1 is ex
Slide 21: Doing now what patients need next
Doing now what patients need next